Loading
companiesCompany
AskGene Pharma
AskGene Pharma is a United States-based biotechnology company running 2 late-stage cancer trials of ASKG915 and Fruquintinib in gastric & gastro-oesophageal junction cancer.
Also called: AskGene Pharma, Inc.
Overview
AskGene Pharma, based in Camarillo, the United States, is a biotechnology company. AskGene Pharma develops cytokine prodrug therapeutics using its SmartKine platform technology, targeting oncology and autoimmune disease indications. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing ASKG915 and Fruquintinib in gastric & gastro-oesophageal junction cancer. The largest, NCT05867420 (A Study of ASKG915 in Patients With Selected Advanced Solid Tumours), plans to enrol 594 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Camarillo, US
Scorecard
All companies#136of 1244 companies, score 42
- approved products +6
- targets +2
- modalities +2
- regions +7
- registry trials +25
1 approved, 0 in phase 3, 0 earlier, 1 targets, 155 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2012
ApprovedSmall-molecule kinase inhibitor (VEGFR1-3)
Fruquintinib · Fruzaqla
A Chinese-discovered pill that blocks the blood-vessel receptors, approved in 2023 for bowel cancer after all standard treatments.
Similar pages
- PersonJin Li
Shares Fruquintinib, Gastric & gastro-oesophageal junction cancer.
- PersonRui-Hua Xu
Shares Fruquintinib, Gastric & gastro-oesophageal junction cancer.